Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.

Caoilfhionn Marie Connolly Jake A RuddyBrian J BoyarskyIulia BarburWilliam A WerbelDuvuru GeethaJacqueline M Garonzik-WangDorry L SegevLisa Christopher-Stine Julie J Paik

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.

Keyphrases

sars cov
end stage renal disease
respiratory syndrome coronavirus
ejection fraction
rheumatoid arthritis
prognostic factors
peritoneal dialysis
early onset
physical activity
patient reported outcomes
data analysis
artificial intelligence